Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.065 AUD | 0.00% | +1.56% | +47.73% |
03/04 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
29/02 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
Sales 2024 * | 6.5M 4.27M 356M | Sales 2025 * | 12.3M 8.09M 674M | Capitalization | 18.9M 12.42M 1.04B |
---|---|---|---|---|---|
Net income 2024 * | -3M -1.97M -164M | Net income 2025 * | 2M 1.31M 110M | EV / Sales 2024 * | 2.49 x |
Net cash position 2024 * | 2.7M 1.78M 148M | Net cash position 2025 * | 5.2M 3.42M 285M | EV / Sales 2025 * | 1.11 x |
P/E ratio 2024 * |
-5
x | P/E ratio 2025 * |
8.13
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.31% |
Latest transcript on Acrux Limited
1 week | +1.56% | ||
Current month | +35.42% | ||
1 month | +38.30% | ||
3 months | -7.14% | ||
6 months | +58.54% | ||
Current year | +47.73% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Kotsanis
CEO | Chief Executive Officer | - | 03/14/03 |
Joanna Johnson
DFI | Director of Finance/CFO | - | 21/21/21 |
Chief Tech/Sci/R&D Officer | - | 15/15/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Geoff Brooke
BRD | Director/Board Member | 68 | 01/16/01 |
Ross Dobinson
FOU | Founder | 72 | 01/98/01 |
Michael Kotsanis
CEO | Chief Executive Officer | - | 03/14/03 |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 0.065 | 0.00% | 50 016 |
02/24/02 | 0.065 | +3.17% | 816,220 |
01/24/01 | 0.063 | -8.70% | 557,826 |
30/24/30 | 0.069 | +13.11% | 688,394 |
29/24/29 | 0.061 | +1.67% | 151,218 |
Delayed Quote Australian S.E., May 03, 2024 at 05:29 am IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+47.73% | 12.36M | |
+20.60% | 43.67B | |
+20.67% | 22.51B | |
+14.56% | 14.6B | |
+14.34% | 13.74B | |
+43.05% | 11.91B | |
-8.37% | 7.04B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.21% | 5.42B |
- Stock Market
- Equities
- ACR Stock